Written by the Nuvirox Research Team
Key points
- The trial that built lion's mane's reputation randomised 30 people with mild cognitive impairment for 16 weeks — and cognitive scores fell back after supplementation stopped.
- Newer trials in healthy adults are mixed: a 41-person study found faster Stroop performance but a stress effect that missed significance, and an 18-person acute study found no overall cognitive or mood effect.
- The nerve growth factor mechanism everyone cites has been shown in cell culture and rodents, not measured in a human brain.
Short answer: there is a real signal in small trials, and the reputation has run far ahead of it. Lion's mane (Hericium erinaceus) contains compounds — hericenones in the fruiting body, erinacines in the mycelium — that stimulate nerve growth factor synthesis in cell culture. That is a genuinely interesting mechanism, and it explains why the mushroom attracted research attention. The human trials that followed are small, short, and inconsistent. The most-cited one had 30 participants, and its most instructive finding is what happened when people stopped taking it.
What is the proposed mechanism?
Nerve growth factor is a neurotrophin — a protein that supports the survival, maintenance, and growth of certain neurons. NGF cannot cross the blood-brain barrier, so the interesting hypothesis is not that lion's mane delivers NGF but that its small-molecule constituents cross into the brain and stimulate local NGF production.
Hericenones and erinacines have both been shown to induce NGF synthesis in cultured cells, and erinacine A specifically has been the focus of several rodent studies. Neurite outgrowth — neurons extending processes — has been demonstrated in vitro. What has not been demonstrated is the corresponding step in a living human: no published trial has measured brain NGF in people taking lion's mane.
The mechanistic chain. Four of five steps have supporting evidence; the one that would connect the mechanism to the claim does not.
What human studies actually show
The 2009 Mori trial is the foundation, and it is small. A double-blind, parallel-group, placebo-controlled trial recruited Japanese men and women aged 50 to 80 diagnosed with mild cognitive impairment. After a two-week preliminary period, 30 subjects were randomised into two groups of 15. The treatment group took four 250 mg tablets of 96% dry Yamabushitake powder three times daily — 3 grams per day — for 16 weeks, with cognitive function assessed using a scale based on the Revised Hasegawa Dementia Scale. Scores improved significantly versus placebo during supplementation.
The detail worth dwelling on is what happened afterward: the benefit diminished after supplementation ended. That cuts two ways. It argues against a durable disease-modifying effect, and it argues for the effect being real rather than a testing artefact, since a practice effect would not reverse. It is also worth noting the lead author's affiliation with a mushroom company's laboratory, which does not invalidate the finding but belongs in the assessment.
A 2023 pilot in young healthy adults found a narrow effect. Docherty and colleagues randomised 41 healthy adults aged 18 to 45 to 1.8 g of Hericium erinaceus or placebo in a double-blind, parallel-groups design, testing both acute effects at 60 minutes and chronic effects at 28 days. Participants performed faster on the Stroop task 60 minutes after a single dose (p = 0.005). A reduction in subjective stress after 28 days approached but did not reach significance (p = 0.051). The authors were careful to note that null and limited negative findings were also observed and that the small sample warranted caution.
A 2025 acute trial found nothing on its primary measures. Surendran and colleagues gave 18 healthy participants aged 18 to 35 a single 3 g dose of a 10:1 fruiting body extract in a randomised, placebo-controlled, double-blinded crossover design, testing cognition and mood 90 minutes later. There was no significant effect on composite measures of global cognitive function or mood. One individual test — a pegboard task — improved. The authors concluded that any benefits may be task or domain specific.
Saitsu 2019 reported improvement at a higher dose. Participants consuming 2.4 g of Hericium erinaceus daily for 12 weeks showed cognitive improvements. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality programme, which reviews this literature independently, catalogues these trials alongside their limitations.
Every notable human trial of lion's mane and cognition. Bar lengths represent participant numbers; the entire published base is smaller than a single mid-sized pharmaceutical trial.
Study snapshot
| Trial | Mori et al., Phytother Res 2009;23(3):367–372 |
| Design | Double-blind, parallel-group, placebo-controlled |
| Participants | 30 adults aged 50–80 with mild cognitive impairment |
| Dose | 3 g/day dried powder (four 250 mg tablets, three times daily), 16 weeks |
| Result | Significant improvement on the cognitive scale; benefit diminished after stopping |
What lion's mane won't do
It will not resolve brain fog with an identifiable cause, and most brain fog has one. Sleep debt, untreated sleep apnoea, thyroid dysfunction, iron or B12 deficiency, depression, perimenopause, and medication effects all produce this symptom, and a mushroom extract addresses none of them. If your fog is new, worsening, or noticed by other people, the appropriate next step is a clinician and a blood panel.
It is also not established as a treatment for any neurological condition. The Mori trial studied mild cognitive impairment, and one 16-week trial in 30 people does not establish a treatment. Products implying otherwise are overstating the evidence considerably.
If you want to try it, what does the evidence suggest?
Doses in trials that found effects range from 1.8 g to 3 g per day of dried fruiting body or equivalent extract. Durations run from a single acute dose to 16 weeks, with the more convincing cognitive findings coming from the longer trials. If you are running your own experiment, 12 weeks at around 2 to 3 grams matches the literature, and a specific measure — a timed task, a work output metric — beats a general impression.
Product quality is an underrated variable. Hericenones concentrate in the fruiting body and erinacines in the mycelium, and many products sold as lion's mane are mycelium grown on grain, where the grain substrate remains in the final powder. Trials used defined preparations; supplements often do not disclose enough to know what you are taking. For comparison with other mushroom and adaptogen options, see our reviews of cordyceps and exercise performance and Rhodiola rosea for fatigue, which has more direct fatigue data than either mushroom.
If your interest is cognitive aging over years rather than clarity this month, the omega-3 literature is larger and its limitations are different. And for another mushroom-derived compound with a stronger biological rationale and weaker interventional data, our piece on ergothioneine is a useful counterpoint. Those looking at stress rather than cognition may find the ashwagandha evidence more relevant.
Frequently asked questions
Fruiting body or mycelium — does it matter?
The two contain different compounds: hericenones are found in the fruiting body, erinacines in the mycelium. Trials have used both, and there is no head-to-head human comparison establishing superiority. The practical concern is that mycelium-on-grain products may contain substantial grain, so a stated extract ratio and a specified plant part are worth looking for.
How long before I notice anything?
The trials showing cognitive change ran 12 to 16 weeks. One study found an acute Stroop effect at 60 minutes and another found nothing acutely, so same-day effects are unreliable at best. Twelve weeks is a fair minimum for evaluating it.
Is lion's mane safe?
It is an edible mushroom with a long culinary history and the trials reported good tolerability. Allergic reactions have been reported, and anyone with mushroom allergies should avoid it. Long-term safety at supplement doses has not been formally studied, since the longest trial ran 16 weeks.
Does it really increase nerve growth factor in people?
Nobody has measured it. NGF induction has been shown in cell culture and neurite outgrowth in rodents, but no published human trial has measured brain NGF after supplementation — measuring it non-invasively is difficult. The mechanism is a hypothesis carried over from laboratory work.
Why do so many people report it working?
Cognitive performance is highly variable day to day, expectation effects are strong for subjective outcomes, and people typically start a nootropic during a low period. That is exactly why the placebo-controlled trials matter more than reports — and why the 2025 crossover study finding no overall effect is informative even though it is small.
From Nuvirox
Why we formulated NAD+ Restore
Cognitive clarity depends partly on how efficiently neurons can produce energy, and that depends on NAD+ — the coenzyme central to converting fuel into ATP, which declines with age. Rather than a mechanism demonstrated only in cell culture, NAD+ Restore uses nicotinamide riboside at 500 mg, a precursor with published human pharmacokinetic data.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Lion's mane has an appealing mechanism and a genuinely thin human evidence base: four notable trials totalling around 120 participants, running from a single dose to 16 weeks, with mixed results. The strongest finding — improved cognitive scores in 30 people with mild cognitive impairment — came with the caveat that the benefit faded after stopping, and from a trial with industry affiliation. The most recent acute trial found no overall effect. That is a reasonable basis for a personal 12-week experiment at 2 to 3 grams per day and a poor basis for confidence. If your brain fog is new or progressing, the more useful step is finding out why.
References
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367–372. PMID: 18844328. DOI: 10.1002/ptr.2634.
- Docherty S, Doughty FL, Smith EF. The acute and chronic effects of lion's mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023;15. PMCID: PMC10675414.
- Surendran G, Saye J, Mohd Jalil SB, et al. Acute effects of a standardised extract of Hericium erinaceus (lion's mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Front Nutr. 2025. DOI: 10.3389/fnut.2025.1405796. PMCID: PMC12018234.
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40:125–131.
- Alzheimer's Drug Discovery Foundation, Cognitive Vitality. Lion's mane (Hericium erinaceus) evidence rating. alzdiscovery.org.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.